Scinai Immunotherapeutics, listed on Nasdaq as SCNI, is a leading biopharmaceutical company specializing in the development, production, and distribution of cutting-edge inflammation and immunology (I&I) biological products. Focused on addressing autoimmune and infectious diseases, the company boasts a state-of-the-art manufacturing facility and a team of highly skilled pharmaceutical industry experts. Not only does Scinai develop its own pipeline of diversified and commercially viable products and platforms, but it also provides comprehensive boutique CDMO services.

Its pioneering nanosized VHH antibody (NanoAb) pipeline targets diseases with significant unmet medical needs. With an unwavering commitment to innovation and quality, Scinai is dedicated to making a lasting impact on global healthcare. From its team of experts to its groundbreaking product portfolio, Scinai is redefining the future of biopharmaceuticals and setting new standards in the industry.

Whether you're an investor, medical professional, or individual seeking cutting-edge healthcare solutions, Scinai is at the forefront of advancing medicine